Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without relatlimab in advanced or metastatic cutaneous squamous cell carcinoma
2024-513637-20-00Phase 2Authorised
- Sponsor
- Salzburger Landeskliniken
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and relatlimab in cutaneous squamous cell carcinoma (cSCC) (2 arms), sponsored by Salzburger Landeskliniken. Primary endpoint: Objective response rate. Planned start Mar 2017; status: authorised.
02
Drugs
nivolumabrelatlimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2024-513637-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513637-20-00.